Skip to main content
Giuseppe Giaccone, MD, Oncology, New York, NY, New York-Presbyterian Hospital

GiuseppeGiacconeMD

Oncology New York, NY

Chief of Thoracic Oncology and Associate Director for Clinical Research at the Sandra and Edward Meyer Cancer Center

Overview of Dr. Giaccone

Dr. Giuseppe Giaccone is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. He received his medical degree from University of Torino Faculty of Medicine and has been in practice 37 years. He is one of 368 doctors at New York-Presbyterian Hospital and one of 368 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Torino Faculty of Medicine
    University of Torino Faculty of MedicineClass of 1980

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2019 - 2025
  • MD State Medical License
    MD State Medical License 2007 - 2020
  • DC State Medical License
    DC State Medical License 2013 - 2020

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC  
    Roy S Herbst, Giuseppe Giaccone, David R Spigel, The New England Journal of Medicine

Other

Press Mentions

  • Q&A with Dr. Mario Gaudino, Newly Appointed Director of the Joint Clinical Trials Office
    Q&A with Dr. Mario Gaudino, Newly Appointed Director of the Joint Clinical Trials OfficeJanuary 29th, 2021
  • Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung Cancer
    Yale Trial Validates Immunotherapy Treatment for Non-Small Cell Lung CancerSeptember 28th, 2020
  • OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020
    OSE Immunotherapeutics Presents Positive Step-1 Phase 3 Results for Tedopi® in NSCLC at the European Society for Medical Oncology Virtual Congress 2020September 21st, 2020
  • Join now to see all

Committees

  • Member (Steering committee), Update Committee of the ASCO NSCLC Expert Panel, American Society of Clinical Oncology 2015 - Present

Professional Memberships

Hospital Affiliations